Infusion of donor-derived CMV peptide-specific CTL after allogeneic HSCT
A Phase I clinical trial of infusion of donor-derived HLA-A*0201-restricted CMV pp65 peptide-specific CTL to reconstitute CMV-specific immunity after allogeneic haematopoietic stem cell transplantation.
Department of Haematology, Westmead Hospital
12 participants
Aug 1, 2001
Interventional
Conditions
Summary
CMV infection or reactivation causes morbidity and mortality in patients after allogeneic HSCT. We aim to adoptively transfer donor-derived CMV-specific CTL to prevent CMV infection and reactivation in these patients.
Eligibility
Inclusion Criteria1
- HLA-A*0201 pos and CMV seropositive donor, 5/6 or 6/6 sib match or 6/6/MUD, GVHD < grade II at the time of infusion, >day 28 post allogeneic HSCT, no recent anti-lymphocyte globulin.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Phase I study of intravenous infusion of monocyte-derived dendritic cell-primed, donor-derived, HLA-A*0201-restricted, CMV pp65 peptide-specific in vitro expanded cytotoxic T lymphocytes on or after day 28 post stem cell infusion.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000213640